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OBJECTIVES: Chronic obstructive pulmonary disease (COPD) has a great impact on
patient’s health-related quality of life (HRQoL). The aims of this study were: 1) to
assess the generic and disease specific HRQoL of COPD patients, and 2) to evaluate
the influence of age and lung function on the patient’s HRQoL. METHODS: In this
observational, cross-sectional study the following information was obtained: age,
lung function (post-bronchodilator forced expiratory volume in one second [FEV1])
and HRQoL (generic: EuroQol five-dimension questionnaire [EQ-5D], disease spe-
cific: St. George’s Respiratory Questionnaire [SGRQ]). Multiple linear regression
model was applied to analyze the effect of age and FEV1 on the HRQoL. RESULTS:
Data collected from 170 patients (mean age 63.8 years, 41.8% male) were analyzed.
The mean EQ-5D score was 0,55 (SD0,21) and the mean SGRQ total score was
56,22% (SD16,19). The multiple linear regression model was successfully applied
to describe the effect of age and FEV1 on the patient’s HRQoL measured by either
EQ-5D (R20,47) or SGRQ (R20,64). Both generic and disease-specific HRQoL were
related with age and lung function (p0.005). CONCLUSIONS: SGRQ and EQ-5D
appear to be reliable and valid for the assessment of HRQoL in COPD patients and
may be used as a non-invasive patient-centered monitoring system as a guide for
the management of COPD. Due to the simplicity of EQ-5D, the use of this instru-
ment can be recommended within routine clinical practice.
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OBJECTIVES:We aimed to explore patients’ perceived positive and negative factors
associated with the use of pharmacological-behavioral combination therapy to
smoking cessation. METHODS: Each patient who visited a drug dependent treat-
ment center was assessed using structured clinical interviews and the Fagerström
Test for Nicotine Dependence (FTND). In-depth interviews were conducted with
patients who agreed to participate in the study. These patients were treated with
behavioral therapy combined with bupropion or nicotine gum and followed up for
three consecutive months. The interview responses were recorded, transcribed
and organized thematically based on emerging codes using an inductive analysis.
RESULTS: Seventeen key informants participated in this study and the mean age
was 38.2 years. Their FTND score varied from 3.0-5.0 and the number of cigarettes
smoked was 3-40 per day. Among these patients 11.8% were able to quit smoking
within 1 month, 29.4% within 2 months, 29.4% within 3 months, and 29.4% could
not quit smoking in any period of the study. Supportive factors to smoking cessa-
tion included supports from family and colleagues, poorer health, role model for
acquaintances, household cost saving, practical advice from encouraging physi-
cians, fear of social blame, smoking-free policy at workplace, and the patients’
proactive strategies to avoid smoking temptation. Nevertheless, some barriers to
smoking cessation were lacking in initiative and readiness to quit smoking; lacking
of family support; incompliance to pharmacological-behavioral therapy; gaining
weight; triggers such as nicotine withdrawal symptoms, stress, being in a party
with smokers; using tobacco as a substitute of other substance; and inconvenient
service time and facility at the treatment center. CONCLUSIONS: This study pro-
vides a framework of interrelated social factors associated with the use of pharma-
cological-behavioral combination therapy to smoking cessation. There is a need for
developing tobacco dependence treatment programs and enabling factors tailored
to meet the needs of patients.
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OBJECTIVES:Most studies assumed defaulters to be similar to smokers in smoking
cessation programmes. Thus, the objective of this qualitative study was to explore
perceptions held by QSC defaulters towards QSC service provision. This study also
examined the smoking and smoking cessation beliefs among the defaulters.
METHODS: Drawing from the patients’ register at two different QSC settings; one
being managed by a team of physicians, medical assistants and nurses while an-
other is managed by the pharmacists, 14 current adult smokers were interviewed
face-to-face, from May 2010 to March 2011. Interviews were audio-recorded and
transcribed verbatim. The data were analyzed using thematic analysis to generate
codes, categories and subsequently themes. RESULTS: This heterogeneous sub-
group of smokers revealed shared ambivalence towards smoking and smoking
cessation, indicating the underlying unreadiness to quit smoking and low self-
efficacy. The dynamic interaction between components of the QSC such as the
degree of relationship established between the health care providers and the effi-
cacy and availability of smoking cessation aids (SCA) were being perceived as ex-
trinsic motivational cues to enable these smokers to quit smoking. Overall these
smokers described the barriers encountered mirrored the unmet expectation; com-
prising of the lack of expected skills and poor attitudes in the health care providers
and the perceived unavailability and ineffective formal smoking cessation aids
provided at the QSC. CONCLUSIONS: It is necessary to optimize the interplay of
extrinsic motivational cues (health care provider and SCA’s factors) in order to
steer these smokers to quit smoking using the QSC approach. This study serves to
underline the need to address a tailored stepped-care approach in these smokers in
relation to gender, socio-economic status and nicotine dependence level, encom-
passing a wider stance in the tobacco control policy.
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OBJECTIVES: The efficacy and safety of omalizumab for the treatment of severe
persistent allergic asthma have been demonstrated in randomised controlled clin-
ical trials. However, there are limited ‘real world’ data on its effects on healthcare
resource utilisation or health-related quality of life (QoL) in UK clinical practice.
METHODS: A 10 centre retrospective observational study (APEX) compared 12
months pre- versus 12 months post-omalizumab initiation in patients aged 12
years with severe persistent allergic asthma. All patients received 1 dose of
omalizumab. Hospital records were reviewed to obtain data on hospital resource
use and routinely used QoL measures e.g. Asthma Quality of Life Questionnaire
(AQLQ ) at baseline (pre-omalizumab), 16 weeks and up to 12 months following
omalizumab initiation. RESULTS: Mean Accident and Emergency department at-
tendances fell by 70% from 1.52 per patient in the 12 months pre-omalizumab to
0.46 in the 12 months post-omalizumab (p0.001). Similarly, mean in-patient hos-
pital admissions fell by 61% from 1.30 to 0.51 (p0.001) and mean in-patient bed
days fell by 70% from 9.10 to 2.74 (p0.001) per patient. In the subgroup of patients
hospitalised for asthma in the 12-months pre-omalizumab (n81), mean in-pa-
tient hospital admissions fell by 70% from 2.19 to 0.65 (p0.001) and mean in-
patient bed days fell by 74% from 14.86 to 3.83 (p0.001) per patient. Other resource
use, such as outpatient attendances (excluding visits made solely for omalizumab
administration), nurse appointments and telephone consultations remained un-
changed following omalizumab initiation. QoL data were not available for all pa-
tients at every time point. However, where data were available, mean AQLQ scores
increased from 3.09 at baseline to 5.01 at 16 weeks (n90) and to 5.22 at 12 months
(n29). CONCLUSIONS: Treatment with omalizumab is associated with a signifi-
cant reduction in unplanned hospital resource utilisation and significant improve-
ments in patients’ QoL.
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OBJECTIVES:Drug use review for the treatment of asthma and assess the impact of
the administrative program to optimize the use of drugs in the Samara region in
2008-2010. METHODS: In 2008 retrospective analysis of drug use in ambulatory
practice based on a database of 90,196 paid prescriptions patients with bronchial
asthma in the Samara region. An analysis of 155 history of 15 clinics. Data on the
consumption of drugs were presented with the ATC/DDD methodology in the form
of DDD/1000 inhabitants day. After the analysis has developed a program that
includes training, administrative controls over the discharge of drugs, medica-
tions, and form a formal application form. In 2009, the evaluation of the implemen-
tation of the optimization program by re-examining the consumption of drugs (105
318 prescriptions paid for) and analysis of hospital records (143 history) RESULTS:
Use of basic products in 2008 amounted to 380, including inhaled corticosteroids
(ICS) was 286, medications to relieve symptoms - 485 DDD 1000 inhabitants/day. In
2009, use of basic drugs increased by 1.6 times to 621, the consumption of inhaled
corticosteroids has increased by 1.7 times to 502 DDD per 1000 inhabitants/day, (p
0.001). In 2009 compared to 2008 the number of patients with nocturnal symp-
toms dropped from 52% to 37%; of hospitalization from 47% to 25%; ambulance call
from 40% to 23%, respectively (p 0.001). CONCLUSIONS: The introduction of a
rational program for the use of drugs with the use of administrative controls in 2009
allowed the drug to optimize the consumption of patients with asthma to improve
asthma control in clinical practice and to reduce the costs of the use of medical
resources.
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OBJECTIVES: This study analyses consumption patterns of fluoroquinolones and
documents in vitro resistance of S. pneumoniae to fluoroquinolones in ambulatory
care in Belgium. METHODS: Data on fluoroquinolone consumption were derived
from IMS Health. Volume of consumption was expressed in terms of the number of
defined daily doses per 1,000 inhabitants per day (DID). Consumption was valued at
public prices pertaining to the year or month of consumption. Respiratory blood
isolates were taken from adults to test in vitro susceptibility of S. pneumoniae to
levofloxacin and moxifloxacin. The S. pneumoniae strains were isolated in 15 clinical
laboratories throughout Belgium. A hundred blood isolates per year were at ran-
dom selected from 2004 to 2009. Susceptibility and resistance of S. pneumoniae was
expressed using the Clinical and Laboratory Standards Institute breakpoints.
RESULTS: Fluoroquinolone consumption increased from 24.1 million € in 1993 to a
maximum of 44.4 million € in 2002, and then decreased to 35.0 million € in 2009. The
volume of fluoroquinolone consumption has fallen consistently from 3.00 DIDs in
2003 to 2.66 DIDs in 2009. Fluoroquinolones were primarily used to treat urinary
tract infections (36% of consumption, volume of 0.95 DIDs) and lower respiratory
tract infections (26% of consumption, volume of 0.70 DIDs). The minimum inhibi-
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